Latest News
Everest Medicines announces positive topline data from multi-centre Phase three Etrasimod clinical trial in Asia
1 December 2023 - Everest Medicines (HKEX 1952.HK), a China-based biopharmaceutical company, announced on Thursday positive topline data from a multi-centre Phase three clinical trial of Etrasimod in Asia intended for the treatment of moderate-to-sev...
Clarity Pharmaceuticals starts registrational Phase III CLARIFY trial
1 December 2023 - Clarity Pharmaceuticals (ASX: CU6), an Australia-based, clinical stage radiopharmaceutical company, announced on Thursday that it has started its registrational Phase III 64Cu-SAR-bisPSMA diagnostic trial in prostate cancer, CLARIFY...
Soligenix's Phase 2a SGX945 clinical trial IND application receives US FDA approval
1 December 2023 - Soligenix, Inc. (Nasdaq: SNGX), a US-based, late-stage biopharmaceutical company, announced on Thursday that it has received approval from the US Food and Drug Administration (FDA) for the Investigational New Drug (IND) application ...
SciNeuro Pharmaceuticals completes dosing in phase one SNP318 study
1 December 2023 - SciNeuro Pharmaceuticals, a China-based clinical stage biotech company developing treatments for neurodegenerative diseases, particularly Alzheimer's Disease (AD) and Parkinson's Disease (PD), announced on Thursday that it...
Calliditas Therapeutics starts phase two setanaxib clinical study
1 December 2023 - Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX), a Sweden-based commercial stage biopharma company, announced on Thursday that it has started a phase two clinical study to assess setanaxib in Alport syndrome, a g...